FDA Warning Letter Will Not Affect Repel-CV PMA, SyntheMed CEO Says
This article was originally published in The Gray Sheet
Executive Summary
An FDA warning letter to SyntheMed will not affect the company's pending PMA for its Repel-CV cardiac surgery adhesion barrier, CEO Robert Hickey says
You may also be interested in...
FDA Panel: Cardiac Surgery Adhesion Barrier Use Should Be Limited To Kids
SyntheMed's Repel-CV cardiac surgery adhesion barrier should be approved only for pediatric patients since pivotal trial data on newborns cannot be extrapolated to the adult population, FDA's Circulatory System Devices advisory panel recommended Sept. 19
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.